11.200 +0.11 (1.04%)
After hours: 6:47PM EDT
|Bid||11.100 x 200|
|Ask||11.200 x 1100|
|Day's Range||10.830 - 12.145|
|52 Week Range||10.830 - 70.000|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.18|
NEW YORK , April 24, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Prothena Corporation plc ("Prothena" ...
PHILADELPHIA , April 24, 2018 /PRNewswire/ -- Kehoe Law Firm, P.C. is conducting a securities investigation on behalf of investors of Prothena Corporation plc (NASDAQ: PRTA) to determine whether Prothena ...
Prothena Corporation plc (NASDAQ:PRTA) is attracting a substantial amount of attention in the biotechnology space early this week on the back of news that the company has decided to discontinue one of its lead development programs. This is a major setback and, as might be expected, Prothena shares have taken a hit in line with […] The post Here’s What Just Happened With Prothena And Kamada appeared first on Market Exclusive.
Neil Woodford’s Patient Capital Trust sustained a blow from Monday’s plunge in Prothena shares, the group revealed on Tuesday, while also disclosing a fall last year the value of its portfolio. Net asset value fell by 2 per cent over the 12 months to December and shares shed 7.2 per cent following losses among stocks like drugs company Circassia and Allied Mind, the trust said in its annual report. Patient Capital also on Tuesday said that the Prothena tumble had knocked the valuation of its holding in the group down by 68 per cent compared with the level it had calculated at the end of last year.
Shares in Prothena (PRTA.O), a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. As a result, Prothena is discontinuing development of the antibody-based medicine for the condition. The news is a win for short sellers who have targeted the stock but a fresh setback for Woodford, one of Britain's best-known fund managers.
Girard Gibbs LLP is investigating claims on behalf of investors of Prothena Corporation (PRTA) involving possible securities law violations. Specifically, our investigation focuses on whether Prothena issued materially misleading business information to the investing public or engaged in other unlawful business practices. To speak privately with an attorney regarding this class action lawsuit investigation, click here.
NEW YORK , April 23, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prothena Corporation plc ("Prothena" or the "Company") (NASDAQ: PRTA). Such ...
The South San Francisco company halted development of a drug for a rare protein-misfolding condition that causes heart problems, resulting in a $534 million drop in market value.
Shares of Prothena crashed early Monday after it scrapped a drug that failed in a Phase 2 study and looked likely to flop in a late-stage test.
Shares plunge after the company announces that it is halting development of its lead pipeline candidate. Here's what investors need to know.
Prothena Corp. PLC shares plummeted 60% in premarket trade Monday after the company said it is discontinuing development of AL amyloidosis therapy NEOD00, the most advanced therapy in its pipeline. The ...
Phase 2b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ...
Phase 2 b PRONTO study did not meet its primary or secondary endpoints Phase 3 VITAL Amyloidosis Study being discontinued based on futility analysis Investor conference call and webcast today at 8:30 AM ...
A pre-market update from Prothena, the Nasdaq-listed biotech which many had hoped had a treatment for amyloidosis in the works, had bad news to convey Monday: As a reminder, Woodford Investment Management ...
NEW YORK, April 12, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) has taken a hit during the early part of this week on the back of news that one of the company’s leading executives, Randall C. Schatzman, who serves as the current CEO of Alder, will be stepping down to make way for Paul B. Cleveland, a member of the Board of […] The post Here’s Why Alder BioPharmaceuticals And Prothena Corporation Are Moving Today appeared first on Market Exclusive.
The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.
Shares of Prothena (PRTA) surged significantly after the company announced a multi-year collaboration with leading company Celgene to develop new therapies for a broad range of neurodegenerative diseases.
Prothena announced a new collaboration with Celgene in which the latter is giving it an upfront $100 million and investing $50 million.
Prothena jumped by doubt digits late Tuesday on a $150 million deal with Celgene to develop treatments for neurodegenerative diseases.
Prothena Corp. shares rallied in the extended session Tuesday after the biotech company said Celgene Corp. was investing and partnering with the company on treatments for neurodegenerative diseases. Prothena ...